Shannon Schrader

1.3k total citations
18 papers, 700 citations indexed

About

Shannon Schrader is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Shannon Schrader has authored 18 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 12 papers in Virology and 5 papers in Emergency Medicine. Recurrent topics in Shannon Schrader's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (10 papers). Shannon Schrader is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (10 papers). Shannon Schrader collaborates with scholars based in United States, United Kingdom and Spain. Shannon Schrader's co-authors include Michael Sension, Alexandra Thiry, Gary Richmond, Christian Marsolais, Princy Kumar, Stanley T. Lewis, Steven P. Weinheimer, Brinda Emu, Willy Rozenbaum and Adriano Lazzarin and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Clinical Infectious Diseases.

In The Last Decade

Shannon Schrader

17 papers receiving 667 citations

Peers

Countries citing papers authored by Shannon Schrader

Since Specialization

Citations

This map shows the geographic impact of Shannon Schrader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shannon Schrader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shannon Schrader more than expected).

Fields of papers citing papers by Shannon Schrader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shannon Schrader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shannon Schrader. The network helps show where Shannon Schrader may publish in the future.

Co-authorship network of co-authors of Shannon Schrader

This figure shows the co-authorship network connecting the top 25 collaborators of Shannon Schrader. A scholar is included among the top collaborators of Shannon Schrader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shannon Schrader. Shannon Schrader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 2023 ·Infectious Diseases and Therapy ·Judith A. Aberg, (unknown), (unknown), (unknown), (unknown), Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy Kumar, Eduardo Sprinz, Margaret Gartland, (unknown), Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio	7
2	1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants 2020 ·Open Forum Infectious Diseases ·William Towner, Edwin DeJesus, Shannon Schrader, Jerome De Vente, Colleen S. McGary, (unknown), Steven P. Weinheimer, (unknown)	4
3	Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 2018 ·New England Journal of Medicine ·Brinda Emu, Jeffrey Fessel, Shannon Schrader, Princy Kumar, Gary Richmond, (unknown), Steven P. Weinheimer, Christian Marsolais, Stanley T. Lewis	153
4	Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1 2017 ·Open Forum Infectious Diseases ·Brinda Emu, (unknown), Shannon Schrader, Princy Kumar, Gary Richmond, (unknown), Steven P. Weinheimer, Christian Marsolais, Stanley T. Lewis	7
5	Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection 2016 ·Open Forum Infectious Diseases ·Jacob Lalezari, (unknown), Shannon Schrader, Princy Kumar, Gary Richmond, Christian Marsolais, Steven P. Weinheimer, Stanley T. Lewis	1
6	Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules 2008 ·AIDS Research and Therapy ·Shannon Schrader, Susan K. Chuck, (unknown), (unknown), (unknown)	10
7	Patient preferences among third agent HIV medications: a US and German perspective 2007 ·AIDS Care ·Kathleen Beusterien, (unknown), Shannon Schrader, Emuella Flood, (unknown), Arran Shearer, Elizabeth Davis	22
8	Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency 2005 ·AIDS Research and Human Retroviruses ·Franco Lori, Richard B. Pollard, Lucia Whitman, Nyasha Bakare, Gary Blick, (unknown), Andrea Foli, D. M. Peterson, Alan M. Tennenberg, Shannon Schrader, Bruce Rashbaum, Charles Farthing, (unknown), D. B. Norris, (unknown), Ian Frank, (unknown), (unknown), David M. Asmuth, Julianna Lisziewicz	9
9	Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: Clinical effectiveness in hypogonadal, HIV-positive males 2005 ·Clinical cornerstone ·Shannon Schrader, Anthony Mills, (unknown), Jon E. Block	13
10	Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Kathleen Squires, Adriano Lazzarin, (unknown), William G. Powderly, Vadim Pokrovskiy, (unknown), Joseph G. Jemsek, Antonio Rivero, Willy Rozenbaum, Shannon Schrader, Michael Sension, Asda Vibhagool, Alexandra Thiry, Michael Giordano	238
11	CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies 2004 ·Clinical Infectious Diseases ·Roberto C. Arduino, Esteban C. Nannini, (unknown), Shannon Schrader, Marcelo Losso, Kiat Ruxrungtham, Maria C. Allende, Sean Emery, Lisa Fosdick, James D. Neaton, Jorge A. Tavel, Richard T. Davey, H. Clifford Lane, (unknown)	31
12	Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial 2004 ·Clinical Infectious Diseases ·E DeJesus, Dennis McCarty, Charles Farthing, Denise Shortino, Beatriz Grinsztejn, Deborah A. Thomas, Shannon Schrader, (unknown), Michael Sension, Kevin Gough, Sarah J. Madison, (unknown)	50
13	Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial 2003 ·AIDS ·David W. Haas, Carlos Zala, Shannon Schrader, Peter J. Piliero, Hans Jaeger, (unknown), Alexandra Thiry, Steven Schnittman, Michael Sension	78
14	Atazanavir plus saquinavir once daily: favorable effects on lipid profiles in patients failing prior protease inhibitor therapy (trial AI424-009) 2002 ·Journal of the American College of Cardiology ·David W. Haas, Carlos Zala, Shannon Schrader, Alexandra Thiry, Rachel T. McGovern, Steven Schnittman	1
15	A Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1 2000 ·The Journal of Infectious Diseases ·James Hellinger, Marika K. Iwane, Jeffery J. Smith, A. Fleishman, Ramón A. Torres, Shannon Schrader, George Perez, Calvin Cohen, Gail Skowron, (unknown), (unknown), Ellen C. Cooper, Kevin R. Frost	18
16	Low-Dose Daily Subcutaneous Interleukin-2 in Combination with Highly Active Antiretroviral Therapy in HIV + Patients: A Randomized Controlled Trial 2000 ·HIV Clinical Trials ·Jacob Lalezari, (unknown), Peter Ruane, Calvin Cohen, (unknown), David J. Sundin, Wai Yie Leong, Stephen Raffanti, David A. Wheeler, Roger D. Anderson, Philip Keiser, Shannon Schrader, (unknown), Corklin Steinhart, Robert L. Murphy, (unknown), Kendall A. Smith	35
17	Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine 1999 ·AIDS ·(unknown), Richard B. Pollard, Shannon Schrader, (unknown), Thomas Kelleher, C. McLaren	22
18	An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice. 1999 ·PubMed ·Richard Elion, (unknown), Cal Cohen, (unknown), Ian M. Baird, Shannon Schrader, Derek Ward	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact